Immix Biopharma (NASDAQ: IMMX)

Last close As at 30/04/2025

USD2.11

0.13 (6.57%)

Market capitalisation

USD54m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Latest Insights

View More

Healthcare | Update

Immix Biopharma — All eyes on NEXICART-2

Healthcare | Flash

Immix Biopharma — NXC-201 receives FDA RMAT designation

Healthcare | Comment

Immix (NASDAQ: IMMX) presents positive data in ALA

Scientist using protective robber gloves for handling substances and experiments

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Cancer cells low poly blue

Flash note

Healthcare

Immix Biopharma — Encouraging stream of ALA data newsflow

Flash note

Healthcare

Immix Biopharma — CAR-T treatment continues to show promise

Cancer cells low poly blue

Update

Healthcare

Immix Biopharma — Pipeline momentum continues in FY23

Scientist using protective robber gloves for handling substances and experiments

Flash note

Healthcare

Immix Biopharma — Encouraging progress on multiple fronts

edison tv

Healthcare

Immix Biopharma – executive interview